Clinical Trial

A Phase I Clinical Study of AHB - 171 in Healthy Participants(HP) and Chronic Hepatitis B (CHB) Participants

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, immunogenicity and Pharmacokinetics (PK) characteristics of AHB-171 Injection in healthy participants (Part A) and participants with chronic hepatitis B (CHB, Part B), and assess its preliminary efficacy in CHB participants.
Protocol Amendment History 3 changes
critical Primary endpoint(s) modified 2026-07-22
critical Recruitment opened 2026-06-02
critical Primary endpoint(s) modified 2026-06-02
Trial Details
NCT Number NCT07511218
Lead Sponsor Ausper Biopharma Co., Ltd.
Conditions Chronic Hepatitis B Infection
Enrollment 110 participants
Start Date 2026-04-13
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-21